Hybridoma and Hybridomics Chimeric TNT-3 Antibody/Murine Interferon-? Fusion Protein for the Immunotherapy of Solid Malignancies
July 2004
...To overcome these obstacles, we have developed an antibody/murine IFN-? fusion protein (chTNT-3/muIFN-?), which utilizes the tumor necrosis therapy antibody, chTNT-3, to target murine IFN-? to necrotic regions of solid tumors implanted in immunocompetent BALB/c mice. The genetically engineered fusion protein was expressed in NS0 cells using the Glutamine Synthetase Gene Amplification Expression System. After purification, the fusion protein demonstrated both antigen targeting and cytokine activities as assessed by in vitro assays which, when compared to recombinant free IFN-?, demonstrated approximately 40–45% biologic activity by two separate assay determinations. Pharmacokinetic and biodistribution studies in mice demonstrated a relatively long whole body half-life of 32 h in vivo and significant intratumoral accretion, respectively.
Market Data 
Markets 
AI
